Drug safety alert: CDSCO flags 58 drug samples
In its latest drug safety alert, the apex drug regulatory body, the Central Standard Control Organisation (CDSCO) has flagged 58 medicine batches for failing to qualify for a random sample test for February 2023, while 2 drug samples have been declared as suprious.
These drugs include Acepik - P (Aceclofenac and Paracetamol Tablets) manufactured by Nexkem Biotech, Amoxycillin Oral Suspension I.P. (Medmoxil 125) manufactured by Laborate Pharmaceuticals, Calcium Carbonate and Vitamin D3 Tablets IP (Calcigiant 500 Tablets) manufactured by Nutra Life Healthcare, Ofloxacin manufactured by Concept Pharmaceutical, Calcium and Vitamin D3 Tablets manufactured by Hanuchem Laboratories, Serratiopeptidase Tablets manufactured by Arnav Research Laboratories.
For more information, click on the link below:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.